$5.11
+0.23(4.71%)
Mkt Cap $72M
$1.80
$5.13
52-Week Range
At a Glance
AI-generated8-K
Grace Therapeutics announced its third quarter fiscal 2026 financial results for the period ended December 31, 2025, reporting a net loss of $2.3 million. The company also provided a business update, highlighting the FDA's PDUFA target date of April 23, 2026, for its NDA for GTx-104 in the treatment of aneurysmal subarachnoid hemorrhage.$72M
Market Cap
—
Revenue
-$6M
Net Income
Employees4
Fundamentals
How The Business Makes Money
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001444192
ISINUS00439U1043
Phone818 839 4378
Address103 Carnegie Center, Princeton, NJ, 08540, US
SEC EDGAR